drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous T cells genetically engineered to express a chimeric antigen receptor targeting CD19, leading to cytotoxic depletion of CD19+ B-lineage cells and a B-cell reset in SLE.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express a chimeric antigen receptor targeting CD19. Upon binding CD19 on B-lineage cells, the CAR T cells become activated and mediate cytotoxic killing of CD19+ B cells and plasmablasts, leading to B-cell depletion and subsequent immune reset with reduced autoantibody production and inflammatory signaling.
drug_name
CD19 CAR-T cells
nct_id_drug_ref
NCT06106906